This finding expands the mutation spectrum of SMAD3 gene and highlights the importance of screening patients with aneurysms as well as early onset osteoarthritis for SMAD3 mutation, which will facilitate identification of at-risk family members and early intervention. This evidence concerns the gene SMAD3 and osteoarthritis.